Ganoderic acid A accelerates osteoporotic fracture healing by promoting osteogenic differentiation via estrogen receptor alpha binding Authors: Kecheng Tang, Yiru Chen, Yan Yu, Zhizhen Huang, Hang Zhang, Yun Tian, Min Li, Yue Yin, Baoxue Yang, Bingchuan Liu Published: 2026 ABSTRACT AbstractObjectivesGanoderic acid A (GAA), a natural triterpenoid derived from the fungal species Ganoderma lucidum which is known for its medicinal properties, is well recognized for its anti-inflammatory, anti-aging, kidney-protective, and hepatoprotective properties. However, its role in osteoporotic fracture (OF) healing remains unclear.This study aims to explore the pharmacological effects of GAA on OF healing and to clarify its underlying mechanisms.MethodsAn ovariectomized femoral fracture model was treated with GAA or estradiol benzoate. Callus formation, mineralization and bone mineral density (BMD) were assessed by micro–computed tomography, radiographic scoring and DXA. Mechanical properties were evaluated by three-point bending tests. Histological analyses and enzyme-linked immunosorbent assay for serum bone formation and resorption markers were performed. RNA sequencing with GO, KEGG and GSEA analyses was used to explore molecular mechanisms. In vitro, MC3T3-E1 cells were used to assess osteogenic differentiation under GAA, estrogen receptor (ER) antagonist (ICI 182780) or selective ERα antagonist (Methyl-piperidino-pyrazole dihydrochloride, MPP) treatment. Biophysical interaction assays and molecular simulations were employed to characterize GAA–ERα interactions.ResultsGAA enhanced early callus mineralization, bone volume fraction, callus volume and trabecular number, and increased radiographic union, bone mineral density and flexural rigidity in OF mice. Histological analysis showed increased soft callus and mineralized bone with elevated bone formation and resorption markers. Transcriptomic analyses indicated that GAA modulated hormone-related pathways, identifying the estrogen signaling pathway as a key target. In vitro, GAA promoted alkaline phosphatase activity, mineral deposition and expressions of phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK1/2), Runt-related transcription factor 2 (RUNX2) and bone morphogenetic protein 2 (BMP2), all of which were abrogated by ICI 182780 and MPP. Notably, molecular interaction studies demonstrated direct and stable binding of GAA to ERα.ConclusionGAA promotes osteogenic differentiation and accelerates OF healing via ERα.The translational potential of this articleThe work offers a conceptual advance by identifying a fungal-derived small molecule that functions as an ERα ligand to promote fracture repair, supporting its potential as a therapeutic candidate for OF.Keywords: Bone formation, Bone resorption, Estrogen receptor alpha, Ganoderic acid A, Osteogenic differentiation, Osteoporotic fractures Introduction Osteoporotic fracture (OF), defined as fractures resulting from low-energy trauma, represents a major global health burden, particularly among postmenopausal women [1]. These injuries are associated with a high lifetime incidence, long-term disability and increased mortality, placing substantial medical and socioeconomic strain on aging populations [2]. Epidemiological studies indicate that nearly half of women over the age of 50 experience at least one OF during their lifetime [3], underscoring the urgent need for safe and effective therapeutic strategies to improve fracture healing in this population. Estrogen replacement therapy has long been an important clinical approach for the management of OF because of its ability to reduce fracture risk and facilitate bone repair [4]. Estrogen maintains skeletal homeostasis by regulating the balance between bone resorption and formation through coordinated modulation of osteoclast and osteoblast activity [5]. During fracture healing, estrogen promotes callus formation and mineralization by enhancing osteoblast proliferation and differentiation, thereby contributing to effective skeletal repair [6]. However, the sharp decline in estrogen levels following menopause disrupts these processes, resulting in impaired bone regeneration, prolonged healing time, and an increased risk of delayed union or non-union [7]. Despite its therapeutic benefits, long-term estrogen replacement therapy is constrained by significant adverse effects. For example, estradiol (E2) increases the risk of breast and endometrial cancer as well as thromboembolic events, whereas raloxifene may elevate the risk of venous thromboembolism and exacerbate vasomotor symptoms such as hot flashes [8,9]. These safety concerns highlight the need to identify alternative therapeutic agents. In this context, dietary estrogenic compounds derived from natural sources have attracted increasing interest as potential therapeutic candidates. These compounds are structurally similar to endogenous 17β-estradiol and are capable of binding estrogen receptors (ERs), thereby functioning as estrogen receptor modulators (ERMs) [10,11]. They exert estrogen-like effects under low-estrogen conditions while displaying antagonistic or weaker agonistic activity when endogenous estrogen levels are high [12]. Such context-dependent activity suggests that dietary estrogenic compounds may offer a safer and more balanced approach for the treatment of postmenopausal OF. Ganoderic acid A (GAA) is a tetracyclic triterpenoid with a lanostane skeleton isolated from the medicinal fungus Ganoderma lucidum. GAA is well recognized for its anti-inflammatory, anti-aging, kidney-protective, and hepatoprotective properties [[13], [14], [15], [16]]. Notably, its steroid-like molecular framework exhibits structural similarity to estrogen, raising the possibility that GAA may function as a fungal-derived ERM. Recent studies have demonstrated that GAA prevents bone loss in lipopolysaccharide-treated male rats by reducing oxidative stress and inflammation [17]. Furthermore, GAA has been shown to prevent osteoporosis in ovariectomized mouse models through modulation of the PIK3CA/p-Akt/TWIST1 signaling pathway [18]. However, these investigations have focused primarily on osteoporosis prevention, and whether GAA can rescue delayed OF healing remains unknown. Moreover, it has not been determined whether GAA directly targets ERs, particularly estrogen receptor α (ERα), to enhance osteogenic differentiation. Based on its structural resemblance to estrogen and its diverse bioactive properties, it is hypothesized that GAA may accelerate OF healing by binding to ERα and promoting osteogenic differentiation. Accordingly, this study investigates whether GAA accelerates OF healing through direct interaction with ERα. By integrating in vivo OF models, in vitro osteogenic differentiation assays, and molecular interaction analyses, this work provides evidence that GAA functions as a direct ERα ligand that enhances osteogenic differentiation and accelerates OF healing. Materials and methods Materials and reagents GAA (HB-01402, purity >98%) was obtained from Wuhan Chemstan Biotechnology Co., Ltd. (Wuhan, China). For in vivo studies, GAA was dissolved in dimethyl sulfoxide (DMSO) (Psaitong, Beijing, Cat# D10043) to prepare a stock solution and subsequently diluted with 20% sulfobutylether-β-cyclodextrin (SBE-β-CD) (Bidepharm, Shanghai, Cat# BD243603) in saline. Estradiol valerate (E2; SE6750) was purchased from Solarbio (Beijing, China) and prepared for in vivo administration using the same procedure. Estradiol (17β-E2:Cat. No. HY-B0141), ICI 182780 (fulvestrant; a nonselective ER antagonist for both ERα and ERβ; Cat. No. HY-13636), Methyl-piperidino-pyrazole dihydrochloride (MPP: a selective ERα antagonist; Cat. No. HY-103454B), and 4-[2-phenyl-5,7bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP: a selective ERβ antagonist; Cat. No. HY-103456) were purchased from MedChemExpress (Shanghai, China). For in vitro experiments, GAA, estradiol, ICI 182780, MPP and PHTPP were dissolved in DMSO. Primary antibodies against ERK1/2 (11257-1-AP), phospho-ERK1/2 (p-ERK1/2; 80031-1-RR), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 60004-1-Ig) were purchased from Proteintech (Wuhan, China). Antibodies against ERα (YT1632) and BMP2 (YM8215) were obtained from ImmunoWay (Yorba Linda, CA, USA). An antibody against RUNX2 (12556T) was purchased from Cell Signaling Technology (Danvers, MA, USA). Enhanced chemiluminescence (ECL) reagents for western blotting (RM00020P) were obtained from ABclonal (Wuhan, China). Recombinant ERα protein (CSB-YP007830HU) was purchased from CUSABIO (Wuhan, China). Animals and procedures Female C57BL/6 mice (12 weeks old; body weight 22–26 g) were housed under specific pathogen-free (SPF) conditions. All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Peking University Health Science Center (Approval No. DLASBE0725). A total of 105 female C57BL/6 mice were randomly assigned to either a sham-operated group (n = 20) or an ovariectomized (OVX) group (n = 85). Bilateral OVX was performed under isoflurane anesthesia as described previously [19]. Sham-operated mice underwent identical surgical procedures without ovary removal. Six weeks after surgery, all mice were subjected to a standardized femoral fracture model as previously reported [20]. Briefly, a metal intramedullary pin was inserted into the femoral canal, followed by generation of a mid-diaphyseal fracture. Radiographic imaging was used to confirm correct pin placement and fracture alignment. Mice received 0.5 mg/kg buprenorphine to control pain [21,22]. Sham-operated mice subjected to fracture were defined as the fracture group, whereas OVX mice subjected to fracture were defined as the OF group. Fractured mice were further randomly assigned to six treatment groups: (1) fracture (n = 20), (2) OF (n = 20), (3) OF + GAA (3.125 mg kg−1; n = 15), (4) OF + GAA (12.5 mg kg−1; n = 15), (5) OF + GAA (50 mg kg−1; n = 20), and (6) OF + estradiol valerate (1 mg kg−1; n = 15). To establish a dose-response relationship and identify the most effective dose for fracture healing, graded doses of GAA were used. Dosages of GAA and E2 were selected based on previous studies [[23], [24], [25]]. GAA and E2 were administered once daily by intraperitoneal injection starting on the first day after fracture surgery and continued for 14 or 28 days. Based on our preliminary study, day 14 and day 28 were selected as the observation time points (Supplementary Fig. 1). At days 14 or 28 post-fracture, mice were deeply anesthetized with isoflurane inhalation. Whole blood was collected via the retro-orbital sinus after deep isoflurane anesthesia. Immediately after blood collection, euthanasia was performed by cervical dislocation while the mice were under deep anesthesia, consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020 Edition). The fractured femora were then harvested for subsequent analyses. Micro–computed tomography (μCT) Following fixation in 4% paraformaldehyde for 24 h, fractured femora were scanned using a μCT system (SkyScan 1276, Bruker, Allentown, PA, USA). Scanning was performed at a voltage of 60 kV, a current of 200 μA, and a voxel resolution of 6.5 μm. For callus analysis, 100 consecutive slices centered on the fracture line (50 slices proximal and 50 slices distal) were selected. μCT analysis software was used to quantify callus bone volume (BV), bone volume fraction (BV/TV), callus volume, and trabecular number (Tb.N), with original cortical bone excluded from the analysis. Whole-body bone density analysis Whole-body bone mineral density (excluding the head and fractured femur) was measured using a small-animal dual-energy X-ray absorptiometry (DXA) system (UltraFocus DXA, Faxitron Bioptics, Tucson, AZ, USA). Data were analyzed using Vision software (Faxitron Bioptics) according to the manufacturer's instructions. Bone biomechanics Mechanical properties of fractured femora were assessed using a three-point bending test performed with a mechanical testing system (Landmark, MTS Systems Corp., Eden Prairie, MN, USA). Each femur was positioned horizontally on two supports with an 8 mm span, and a vertical load was applied at the midpoint of the diaphysis. The crosshead was advanced at a constant displacement rate of 6 mm min−1 until failure. Load–displacement curves were recorded for analysis. Bone formation and resorption markers Serum levels of osteocalcin (OCN), N-terminal propeptide of type I procollagen (PINP) and β-C-terminal telopeptide of type I collagen (β-CTX) were quantified using enzyme-linked immunosorbent assay (ELISA) kits (Yojanbio, Shanghai, China; OCN, YJ-E-30074M; PINP, YJ-E-95791Q; β-CTX, YJ-E-96654Q), according to the manufacturer's instructions. Absorbance was measured at 450 nm using a microplate reader, and analyte concentrations were calculated from standard curves. Histological and immunohistochemical analyses Following fixation, femoral specimens were decalcified by gentle agitation in 10% ethylenediaminetetraacetic acid (EDTA; pH 7.4) for 21 days. Samples were then processed using a standard protocol involving dehydration through a graded ethanol series, paraffin embedding, and sectioning to obtain 5 μm-thick sections. Immunohistochemical staining was performed to detect Type II collagen alpha 1 chain (COL2A1) and type I collagen alpha 1 chain (COL1A1). For histological evaluation of callus composition and bone remodeling, Masson's trichrome, Safranin O and Fast Green (SO & FG), Goldner's trichrome, and tartrate-resistant acid phosphatase (TRAP) staining were performed on hard-tissue sections prepared using a precision cutting and grinding system (EXAKT, Norderstedt, Germany). All stained sections were imaged and quantitatively analyzed using ImageJ software. Illumina RNA sequencing of fractured femurs Total RNA was extracted from fractured femoral tissues collected from three experimental groups—fracture, OF, and OF treated with GAA (50 mg kg−1)—with n = 4–5 biological replicates per group. The 50 mg/kg dose was selected for RNA-seq because it represented the most appropriate experimental condition for mechanistic profiling, as the representative high-effective dose. RNA samples were submitted to Gene Denovo Biotechnology Co., Ltd. (Guangzhou, China) for library preparation and sequencing on an Illumina platform. differentially expressed genes (DEGs) were identified using the DESeq2 package, with significance defined as |log2(fold change)| ≥ 1 and an adjusted p value ≤ 0.05. Functional enrichment analyses were performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. gene set enrichment analysis (GSEA) was further conducted to identify enriched biological pathways and processes. Cell culture and osteogenic differentiation MC3T3-E1 subclone 14 cells (Eallbio, Beijing, China; Cat. No. 06.0876) were cultured in MC3T3-E1 subclone 14 complete medium (Eallbio; Cat. No. 03.20240) at 37 °C in a 5% CO2 humidified atmosphere. Cells at passages 3–10 were used for experiments. For osteogenic induction, cells were cultured in osteogenic differentiation medium (Eallbio; Cat. No. 03.18041B), which was replaced every 2–3 days for 7 or 14 days. According to the manufacturer's specifications, the osteogenic medium contained β-glycerophosphate, ascorbic acid, and dexamethasone. Cytotoxicity assay in MC3T3-E1 subclone 14 cells To test the toxicity of GAA, MC3T3-E1 cells were treated with different concentrations (0–200 μM) of GAA for 24 h, 48 h and 72 h. The viability of the cells was then analyzed using the CCK-8 assay (Eallbio, Beijing, China; Cat. No. 03.17002DB) [26]. Alkaline phosphatase and Alizarin Red S staining Osteogenic differentiation was assessed at two time points. On day 7, Alkaline phosphatase (ALP) activity was evaluated. Cells were washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 10 min, and stained using an ALP staining kit (Beyotime Biotechnology; C3206). On day 14, extracellular matrix mineralization was assessed by Alizarin Red S (ARS) staining using a commercial kit (OriCell; ALIR-10001) following fixation. Images were acquired using an inverted microscope (Nikon TE2000-S; Nikon Instruments, Melville, NY), and the stained areas were quantified using ImageJ software. Western blotting analysis Proteins were extracted from MC3T3-E1 cells and fracture callus tissue using standard lysis procedures. Equal amounts of protein (50 μg per lane) were separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% non-fat milk in Tris-buffered saline containing Tween-20 (TBST) for 2 h at room temperature and incubated overnight at 4 °C with primary antibodies against β-actin, GAPDH, ERα, p-ERK1/2, total ERK1/2, BMP2, and RUNX2. After washing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (SA00001-1 or SA00001-2) for 2 h at 25 °C. Protein bands were visualized using an enhanced chemiluminescence detection system, and band intensities were quantified using a BioSpectrum gel imaging system. Molecular docking Molecular docking analysis was performed using the CB-Dock2 platform (https://cadd.labshare.cn/cb-dock2/php/index.php). The three-dimensional crystal structure of ERα ligand-binding domain was obtained from the RCSB Protein Data Bank (PDB: 6VPF). This structure represents the ERα ligand-binding domain in complex with the selective estrogen receptor modulator (SERM) clomiphene [27]. Prior to docking, water molecules and co-crystallized ligands were removed, polar hydrogens were added, and the protein structure was energy-minimized. CB-Dock2 automatically identified binding cavities and performed docking using the AutoDock Vina scoring function to determine optimal binding poses. The top-ranked docking conformations were visualized and analyzed using LigPlot+ (v2.2.9) and PyMOL (v2.0; Schrödinger, New York, NY, USA). Cellular thermal shift assay Cellular thermal shift assay (CETSA) was performed as previously described [28]. MC3T3-E1 cells were seeded in six-well culture plates (Corning, NY, USA) at a density of 1 × 106 cells per well and allowed to adhere overnight. Cells were then treated with GAA (200 μM) or vehicle control (0.1% DMSO) for 24 h. Following treatment, cells were washed with ice-cold PBS, harvested by scraping, and subjected to three rapid freeze–thaw cycles in liquid nitrogen to obtain protein lysates. Lysates were divided into eight equal aliquots and heated for 3 min at temperatures ranging from 34 to 55 °C in 3 °C increments, followed by cooling at 4 °C for 3 min. After centrifugation (12,000 × g, 15 min, 4 °C) to remove precipitated proteins, the supernatants were analyzed by western blotting to assess the thermal stability of ERα. Microscale thermophoresis The interaction between ERα and GAA was examined using microscale thermophoresis (MST) according to a previously reported protocol [29]. Recombinant ERα protein was fluorescently labeled using a Monolith NT.115 labeling kit (NanoTemper Technologies GmbH, Munich, Germany). The labeled protein was incubated with increasing concentrations of GAA for 30 min at room temperature. Binding affinities were measured using a Monolith NT instrument, and the equilibrium dissociation constant (KD) was calculated using the NT analysis software. Surface Plasmon Resonance analysis Surface Plasmon Resonance (SPR) Analysis experiments were performed using a Biacore T200 system (GE Healthcare, Uppsala, Sweden). Recombinant ERα protein was immobilized on a CM5 sensor chip (Cytiva, Cardiff, Wales, UK) via standard amine-coupling chemistry. The running buffer was PBS with 0.05% Tween 20 (PBST). Binding interactions between ERα and GAA were analyzed at a flow rate of 30 μL min−1 using a multi-cycle kinetics mode, with association and dissociation phases monitored for 300 s each. Sensorgrams were recorded as response units (RU) over time and analyzed using Biacore X-100 software (GE Healthcare) to determine binding kinetics. Molecular Dynamics Simulation Molecular Dynamics Simulation (MD) simulations (100 ns) were conducted using the GROMACS 2022 software package. Parameters for GAA were generated using the General AMBER Force Field (GAFF), with geometry optimization performed using Gaussian 16W. Protein–ligand interactions were modeled using the AMBER99SB-ILDN force field, and the system was solvated with the TIP3P water model. Binding free energy and Gibbs free energy were calculated using tools implemented within the GROMACS suite. Statistical analyses All data are presented as means ± standard error of the mean (S.E.M.), except for the radiographic union score which is shown as median. Statistical analyses were performed using GraphPad Prism (version 9.0). Comparisons among multiple groups were conducted using one-way analysis of variance (ANOVA), followed by Bonferroni or Tukey post hoc tests as appropriate. For the ordinal radiographic score, the Kruskal-Wallis test followed by Dunn's test with Bonferroni correction was used. Differences were considered statistically significant when p < 0.05. Results Ganoderic acid A promotes osteoporotic fracture healing The therapeutic effects of GAA on OF healing were evaluated using μCT, DXA, and three-point bending tests. At the early stage of fracture healing (day 14 post-fracture), μCT three-dimensional reconstruction revealed reduced callus mineralization in the OF group compared with the fracture group (Fig. 1A). Quantitative analysis confirmed that OF mice exhibited a significantly lower bone volume fraction (BV/TV) than fracture controls, whereas treatment with GAA or E2 restored BV/TV (Fig. 1B). In addition, GAA treatment significantly increased callus volume (Fig. 1C) and Tb.N (Fig. 1D) at this time point, indicating enhanced early callus formation and mineralization. At the later stage of healing (day 28 post-fracture), differences in BV/TV among groups were largely normalized; however, mice treated with GAA exhibited a significantly higher radiographic union score than those in the OF group (Fig. 1E), suggesting improved maturation of fracture repair. Consistent with these findings, DXA analysis demonstrated a systemic skeletal benefit, as both GAA and E2 significantly increased whole-body bone mineral density on day 28 (Fig. 1F and G). Moreover, mechanical testing revealed that 28 days of treatment with GAA or E2 significantly improved the biomechanical properties of the healed femora, as evidenced by increased maximum load and maximum stress (Fig. 1H and I). Collectively, these results indicate that GAA not only corrects early deficits in callus formation and mineralization in OF mice but also promotes later-stage structural remodeling, thereby effectively enhancing OF healing. GAA enhances OF healing in mice. (A) Representative μCT three-dimensional reconstructions of fractured femora on days 14 and 28 post-fracture. (B) BV/TV of the callus. (C) Callus volume. (D) Tb.N of the callus. (E) Radiographic union score of the callus. (F) Representative DXA images of whole-body bone density. (G) Whole-body bone mineral density. (H) Maximum load. (I) Maximum stress. Data are presented as means ± S.E.M, except for the radiographic union score (Fig. 1E), which is shown as median. (n = 5). **p < 0.01 versus fracture group; #p < 0.05, ##p < 0.01 versus OF group. GAA enhances soft callus formation and endochondral ossification during of healing COL2A1 immunohistochemical staining (cartilage, brown), SO & FG (cartilage, red; mineralized bone, green), and Masson's trichrome staining (cartilage, blue; mineralized bone, red) were used to evaluate soft callus formation and endochondral ossification during OF healing. From day 14 to day 28 post-fracture, the fracture group exhibited a progressive decrease in cartilaginous tissue accompanied by a gradual increase in mineralized bone, consistent with normal endochondral ossification. Compared with the fracture group, OF mice displayed a markedly reduced cartilage area at day 14 and diminished mineralized bone content at day 28 post-fracture (Fig. 2A and B). In contrast, treatment with GAA or E2 increased the cartilaginous area of the callus at day 14 and enhanced mineralized bone formation at day 28 (Fig. 2C–E). Collectively, these results demonstrate that GAA effectively promotes soft callus formation and endochondral ossification during OF healing. GAA enhances soft callus formation and endochondral ossification during OF healing. (A) Representative COL2A1 immunohistochemical staining, SO & FG, and Masson's trichrome staining of callus tissue at day 14 post-fracture. (B) Representative COL2A1 immunohistochemical staining, SO & FG, and Masson's trichrome staining of callus tissue at day 28 post-fracture. (C) COL2A1 positive area. (D) Safranin O staining positive area. (E) Collagen-positive area by Masson staining. Data are presented as means ± S.E.M. (n = 5). **p < 0.01 versus fracture group; #p < 0.05, ##p < 0.01 versus OF group. GAA enhances osteoblast and osteoclast activity during of healing Goldner's trichrome staining (new bone, red), COL1A1 immunohistochemical staining (new bone, brown), and TRAP staining (osteoclasts, red) were performed to evaluate osteoblast and osteoclast activity during OF healing. Compared with the fracture group, OF mice exhibited markedly reduced positive staining areas for Goldner's trichrome, COL1A1, and TRAP at both day 14 and day 28 post-fracture. Treatment with GAA or E2 effectively reversed these reductions (Fig. 3A–D). In addition, serum markers of bone formation, including OCN and PINP, as well as the bone resorption marker β-CTX, were quantified by ELISA. Treatment with GAA or E2 significantly increased serum levels of OCN (Fig. 3E), PINP (Fig. 3F), and β-CTX (Fig. 3G) at both day 14 and day 28 post-fracture compared with OF mice. Collectively, these results indicate that GAA enhances both osteoblast and osteoclast activity during OF healing. GAA enhances osteoblast and osteoclast activity during OF healing. (A) Representative images of Goldner's trichrome staining, COL1A1 immunohistochemical staining, and TRAP staining of callus tissue at days 14 and 28 post-fracture. (B) Goldener positive area. (C) COL1A1 positive area. (D) TRAP positive area. (E) Serum OCN. (F) Serum PINP. (G) Serum β-CTX. Data are presented as means ± S.E.M. (n = 5). **p < 0.01 versus fracture group; #p < 0.05, ##p < 0.01 versus OF group. GAA activates estrogen signaling during of healing To elucidate the molecular mechanisms underlying the effects of GAA, RNA sequencing (RNA-seq) was performed on fractured femoral tissues collected from three experimental groups: fracture, OF, and OF treated with GAA (50 mg kg−1). Principal component analysis (PCA) revealed clear segregation among the three groups, indicating distinct transcriptional profiles (Fig. 4A). Differential expression analysis identified 7149 DEGs between the fracture and OF groups, including 2802 upregulated and 4347 downregulated genes. Comparison between the OF and OF + GAA (50 mg kg−1) groups revealed 1602 DEGs, comprising 1393 upregulated and 209 downregulated genes (Fig. 4B). GO enrichment analysis indicated that GAA modulates multiple hormone-related biological processes, including regulation of hormone levels, hormone secretion, response to steroid hormone, and response to estrogen (Fig. 4C). Consistent with these findings, KEGG pathway enrichment analysis and GSEA identified the estrogen signaling pathway as a prominently regulated pathway in response to GAA treatment (Fig. 4D and E). Furthermore, heatmap analysis of key target gene expression in the estrogen signaling pathway, together with GSEA focusing on the MAPK signaling pathway and PI3K-AKT signaling pathway, confirmed that GAA treatment significantly regulates a series of classic estrogen-responsive genes and activates these critical downstream signaling nodes (Fig. 4E-F). Collectively, these transcriptomic data indicate that GAA facilitates OF healing through activation of estrogen signaling. Transcriptomic analysis reveals activation of estrogen signaling during OF healing. (A) PCA of gene expression profiles in fracture, OF, and OF treated with GAA (50 mg kg−1) groups. (B) Volcano plots showing DEGs between fracture versus OF and OF versus OF + GAA (50 mg kg−1) groups. (C) GO enrichment analysis of DEGs. (D) KEGG pathway enrichment analysis of DEGs. (E) Heatmap of target gene expression in the estrogen signaling pathway (F) GSEA highlighting the estrogen signaling pathway, MAPK signaling pathway and PI3K-AKT signaling pathway. Data were derived from n = 4–5 biological replicates per group. GAA upregulates ERα and p-ERK1/2 levels in fracture callus tissue To validate the transcriptomic findings at the protein level, we performed western blot analysis on whole-callus lysates at day 14 and day 28 post-fracture. ERα protein was readily detectable in the callus tissue, and GAA treatment significantly upregulated its expression compared to the OVX fracture group (Fig. 5A and B). Furthermore, GAA treatment markedly increased the levels of phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) in the fracture callus (Fig. 5A and B). These data provide direct protein evidence that GAA upregulates ERα expression and activates downstream ERK signaling in the fracture callus, consistent with the transcriptomic analysis. GAA upregulates ERα and p-ERK1/2 levels in fracture callus tissue. (A) Representative western blot images showing the expression of ERα, p-ERK1/2, T-ERK1/2 and GAPDH. (B) Quantification of ERα/GAPDH and p-ERK1/2/T-ERK1/2 expression. Data are presented as means ± S.E.M. (n = 3). **p < 0.01 versus fracture group; #p < 0.05, ##p < 0.01 versus OF group. GAA promotes osteogenic differentiation via activation of estrogen receptor–mediated signaling To exclude the potential cytotoxicity of GAA, we confirmed that GAA at 0–200 μM did not affect MC3T3-E1 cell viability (Supplementary Fig. 2). To evaluate the effects of GAA on osteogenic differentiation, MC3T3-E1 cells were cultured in osteogenic medium and treated with GAA in the presence or absence of the estrogen receptor (ER) antagonist ICI 182780. ALP, a marker of early-stage osteogenic differentiation, was assessed by ALP staining, whereas calcium deposition, a marker of late-stage osteogenic differentiation, was evaluated by ARS staining. Compared with the control group, treatment with ICI 182780 (1 μM) markedly reduced the number of ALP-positive nodules and the formation of mineralized calcium nodules, indicating that inhibition of ER signaling impairs osteogenic differentiation. In contrast, GAA treatment increased ALP staining intensity and mineral deposition in a dose-dependent manner, and these pro-osteogenic effects were abolished by co-treatment with ICI 182780 (Fig. 6A and B). Consistent with these observations, western blot analysis demonstrated that GAA increased the level of p-ERK1/2 without altering total ERα expression, and significantly upregulated the osteogenic markers Runt-related transcription factor 2 (RUNX2) and bone morphogenetic protein 2 (BMP2). Notably, these effects were effectively blocked by ICI 182780 (Fig. 6C and D). Collectively, these results indicate that GAA promotes osteogenic differentiation of MC3T3-E1 cells via activation of ER-mediated signaling. GAA promotes osteogenic differentiation in MC3T3-E1 cells. (A) ALP staining of MC3T3-E1 cells on day 7. (B) ARS staining of MC3T3-E1 cells on day 14. (C) Representative western blot images showing the expression of ERα, p-ERK1/2, T-ERK1/2, RUNX2, BMP2, and GAPDH. (D) Quantification of ERα/GAPDH, p-ERK1/2/T-ERK1/2, RUNX2/GAPDH, and BMP2/GAPDH expression. Data are presented as means ± S.E.M. (n = 3). *p < 0.05, **p < 0.01 versus ICI 182780 group; ##p < 0.01 versus control group; &&p < 0.01 versus GAA (100 μM) group. GAA promotes osteogenic differentiation via estrogen receptor α To investigate whether GAA exerts its effects through ERα or ERβ, and to compare the osteogenic effects of GAA with those of 17β-E2, MC3T3-E1 cells were cultured in osteogenic differentiation medium supplemented with GAA in the presence of an ERα antagonist (MPP) or an ERβ antagonist (PHTPP), or with 17β-E2 in the presence or absence of the ERα or ERβ antagonist. As shown in Fig. 7A and B, the osteogenic differentiation–promoting effect of GAA was abolished by MPP (1 μM) but maintained in the presence of PHTPP (0.2 μM). Similarly, 17β-E2 (0.1 μM) also enhanced osteogenic differentiation, and this effect was abolished by MPP yet maintained in the presence of PHTPP. These findings indicate that GAA promotes osteogenic differentiation through ERα rather than ERβ. GAA promotes osteogenic differentiation via ERα. (A) ALP staining of MC3T3-E1 cells on day 7. (B) ARS staining of MC3T3-E1 cells on day 14. Data are presented as means ± S.E.M. (n = 3). *p < 0.05, **p < 0.01 versus control group; ##p < 0.01 versus GAA (100 μM) + PHTPP group; &&p < 0.01 versus 17β-E2+PHTPP group. GAA directly targets ERα To determine whether ERα is a direct molecular target of GAA, molecular docking, CETSA, MST, and SPR analyses were performed. Molecular docking using AutoDock and visualization with PyMOL revealed that GAA occupies the ligand-binding pocket of ERα with a predicted binding free energy of −9.0 kcal mol−1, forming multiple stabilizing interactions with surrounding residues (Fig. 8A). The chemical structure of GAA is shown in Fig. 8B. SPR analysis demonstrated direct binding between GAA and ERα, yielding an equilibrium dissociation constant (KD) of 4.84 μM (Fig. 8C). This interaction was independently confirmed by MST analysis, which showed a KD value of 10.02 μM (Fig. 8D). Furthermore, CETSA performed in MC3T3-E1 cells revealed that GAA treatment increased the thermal stability of ERα, with a Tm shift (ΔTm) of 4.01 °C (Fig. 8E). Collectively, these results demonstrate that ERα is a direct binding target of GAA. GAA directly binds to ERα. (A) Molecular docking model illustrating the interaction between GAA and the ligand-binding domain of ERα, with key interacting residues highlighted. (B) Chemical structure of GAA. (C) SPR sensorgrams and binding curve showing the interaction between ERα and GAA, with the calculated equilibrium dissociation constant (KD). (D) MST analysis of the binding affinity between ERα and GAA, including normalized fluorescence traces and dose–response fitting. (E) CETSA of ERα in MC3T3-E1 cells treated with GAA or DMSO across the indicated temperature range, with representative immunoblots (left) and quantitative analysis (right). GAA forms a stable complex with ERα To assess the binding stability between GAA and ERα, MD simulations were performed. Multiple structural and energetic parameters were analyzed, including root-mean-square deviation (RMSD), ligand RMSD, radius of gyration (Rg), root mean square fluctuation (RMSF), solvent-accessible surface area (SASA), and hydrogen bond interactions. The ERα–GAA complex reached equilibration within the first 20 ns, after which the backbone RMSD remained stable between 0.4 and 0.6 nm, indicating overall structural stability (Fig. 9A). The ligand RMSD fluctuated within a narrow range of 0.05–0.15 nm, suggesting a consistently stable binding pose (Fig. 9B). The Rg value remained between 2.3 and 2.4 nm throughout the simulation, reflecting a compact protein conformation (Fig. 9C). Consistently, SASA gradually decreased from approximately 240 to 210 nm2, indicating conformational compaction of the complex (Fig. 9D). RMSF analysis showed that most ERα residues exhibited fluctuations below 0.25 nm, with limited flexibility confined to the N-terminal and loop regions (Fig. 9E). The number of hydrogen bonds between GAA and ERα fluctuated dynamically between 2 and 4 over time, reflecting persistent intermolecular interactions (Fig. 9F). Structural snapshots highlighted arginine 436 (ARG436) as a key residue mediating ERα–GAA interactions during the simulation (Fig. 9G). Binding free energy analysis using the molecular mechanics/Poisson–Boltzmann surface area (MM/PBSA) method yielded a total binding free energy (ΔGtotal) of −38.44 kcal mol−1, indicating strong binding affinity (Fig. 9H). The Gibbs free energy landscape revealed a dominant low-energy basin centered at RMSD values of 0.3–0.61 nm and Rg values of 2.32–2.36 nm, confirming thermodynamic stability of the complex (Fig. 9I). Electrostatic potential surface analysis further supported high-affinity binding at the ERα–GAA interface, with a docking score of −59.79 (Fig. 9J). Together, these results demonstrate that GAA forms a stable and energetically favorable complex with ERα. GAA forms a stable complex with ERα. (A) Backbone RMSD of the ERα–GAA complex during the 100 ns MD simulation. (B) RMSD of GAA within the ERα binding pocket. (C) Rg of the ERα–GAA complex. (D) SASA of the complex. (E) RMSF of ERα residues. (F) Time evolution of hydrogen bonds between GAA and ERα. (G) Representative structural snapshots of the ERα–GAA complex at selected simulation time points, highlighting key interacting residues. (H) Mean binding free energy components and total binding free energy (ΔGtotal) of the ERα–GAA complex calculated using the MM/PBSA method. (I) Two-dimensional Gibbs free energy landscape of the ERα–GAA complex as a function of RMSD and Rg. (J) Electrostatic potential surface of the ERα–GAA binding interface. Discussion The purpose of this study was to determine the pharmacological effects of GAA, a triterpenoid isolated from G. lucidum, on OF healing. The findings provide the first evidence that GAA accelerates fracture repair in osteoporotic mice by promoting osteogenic differentiation through direct binding to ERα. Osteoporotic fractures are frequently associated with delayed union or nonunion [30]. Fracture healing is a highly orchestrated biological process classically divided into four overlapping stages [31]. The initial inflammatory phase is triggered by hematoma formation immediately after injury. This is followed by the soft callus phase, during which recruited mesenchymal progenitors differentiate into chondrocytes, resulting in the formation of fibrocartilaginous tissue bridging the fracture gap. Subsequently, during the hard callus phase, the cartilage template is progressively resorbed and replaced by woven, mineralized bone through endochondral ossification. Finally, the remodeling phase involves coordinated osteoblastic and osteoclastic activity, transforming woven bone into mature lamellar bone and restoring the original bone architecture and mechanical properties [32,33]. Healing of OF is compromised in both early and late phases, with reductions in callus formation and mechanical strength [34,35]. The impaired repair process is multifactorial, involving diminished osteoblastic responsiveness, reduced angiogenesis, and declines in both the number and functional capacity of mesenchymal stem cells [36]. Consistent with these observations, the present data demonstrate that osteoporosis profoundly disrupts fracture healing, particularly soft callus formation, endochondral ossification, and the coordinated activity of osteoblasts and osteoclasts. OF mice exhibited a marked reduction in soft callus area at day 14 post-fracture, followed by decreased mineralized bone content at day 28, indicating delayed endochondral ossification and impaired callus maturation. Importantly, GAA treatment effectively rescued these defects. Enhancement of early soft callus formation translated into increased mineralized bone content at later stages, thereby supporting accelerated callus maturation. Notably, GAA increased the activity of both osteoblasts and osteoclasts, rather than simply suppressing bone resorption. This balanced activation appears to facilitate efficient callus turnover and replacement of woven bone with mechanically stronger lamellar bone during remodeling. Collectively, these findings demonstrate that GAA accelerates OF healing across both early and late phases of repair. Estrogen receptor signaling is a critical regulator of fracture healing [37]. Estrogen deficiency, commonly modeled by ovariectomy (OVX), impairs early callus formation and delays endochondral ossification [38]. During later stages of repair, estrogen deficiency results in sluggish callus remodeling. Previous studies have shown that estrogen depletion prolongs the inflammatory phase and compromises endochondral ossification, leading to reduced mechanical strength of the healed bone—effects that can be reversed by E2 supplementation [39]. At the cellular level, estrogen enhances alkaline phosphatase activity and calcium mineralization in osteoblast-like MC3T3-E1 cells, whereas ER antagonism using ICI 182780 markedly attenuates these effects [40,41]. In the present study, transcriptomic analyses revealed activation of estrogen signaling in fractured femora following GAA treatment. Moreover, our in-depth bioinformatic analyses of the RNA-seq data identified the PI3K/AKT and MAPK signaling pathways as key downstream nodes, and showed that GAA treatment significantly regulated a series of classic estrogen-responsive genes. To further substantiate the in vivo mechanism, we performed western blot analysis on fracture callus tissue and confirmed that GAA treatment upregulated the expression of ERα and p-ERK1/2 in the callus. These findings were further supported by in vitro data showing that GAA promoted osteogenic differentiation and upregulated ER-associated signaling molecules, effects that were abolished by ER inhibition. Together, these results indicate that GAA accelerates OF healing by promoting osteogenic differentiation through activation of ER-mediated signaling pathways. ERs exert distinct and sometimes opposing roles in bone biology. Studies employing whole-body and bone cell–specific knockout models have demonstrated that deletion of ERα in female mice leads to significant reductions in trabecular and cortical bone mass, accompanied by compromised biomechanical properties [42,43]. In contrast, ERβ deletion produces an opposite skeletal phenotype, characterized by increased bone mineral density and bone volume fraction [44]. These findings highlight a dominant role for ERα in bone homeostasis and fracture repair. GAA possesses a steroid-like molecular framework that resembles estradiol, an endogenous ERα agonist. However, whether ERα represents a direct molecular target of GAA had remained unclear. In this study, the promoting effect of GAA on osteogenic differentiation was abolished by the selective ERα antagonist but maintained in the presence of the selective ERβ antagonist. Furthermore, through an integrated approach combining molecular docking, MD simulations, CETSA, MST, and SPR analyses, specific and direct binding between GAA and ERα was demonstrated, establishing ERα as a direct molecular target of GAA. 17β-Estradiol binds ERα through a canonical hydrogen-bond network involving Glu353, Arg394 and His524 [45]. In contrast, our MD simulations show that GAA engages a distinct set of residues within the same ligand-binding domain, primarily ARG436, ASP426 and ARG412, with auxiliary contributions from SER463, SER433 and PRO399. This shifted hydrogen-bonding pattern indicates that GAA adopts a non-canonical binding mode distinct from the classic estrogen agonist. Several phytoestrogens acting via ERα have been studied for bone protection, including icariin [46] and formononetin [47], but they are mostly flavonoids. In contrast, GAA is a lanostane-type triterpene, which is rarely reported for ERα-targeted bone effects. Moreover, unlike most phytoestrogens (e.g., genistein) that prefer ERβ [48], our study shows that GAA selectively binds and acts through ERα. Additionally, GAA possesses anti-inflammatory and anti-aging properties that conventional phytoestrogens lack. These unique features collectively highlight the novelty of exploring GAA as an ERα-selective, multi-target bone-protective agent. Identification of GAA as a fungal-derived ERM carries significant translational implications. Currently available agents for OF management, including recombinant human bone morphogenetic protein-2 (rhBMP-2), bisphosphonates, and parathyroid hormone (PTH) analogs, are limited by high cost, restricted indications, or long-term safety concerns [49,50]. E2 therapy increases the risk of breast and endometrial cancer and thromboembolic events; rhBMP-2, although potent, is costly and associated with local complications; bisphosphonates suppress bone turnover and do not consistently accelerate fracture healing; and PTH analogs require prolonged systemic administration and are constrained by safety considerations. These limitations underscore the need for alternative therapeutic strategies. In contrast to conventional estrogen replacement therapy, GAA is a natural compound with a long history of medicinal use and reported geroprotective propertie. Moreover, the safety data of GAA have been well established in a previous study: middle-aged mice fed a diet containing GAA (120 mg/kg) for three months showed no abnormalities in appearance or behavior, no significant changes in biochemical parameters, and no organ toxicity [51]. In our study, CCK-8 assays demonstrated that GAA at 0–200 μM did not affect MC3T3-E1 cell viability. The present findings demonstrate that GAA enhances early callus formation, increases BV/TV and radiographic union, and improves biomechanical strength of healed bone, supporting its potential as a novel therapeutic option for postmenopausal OF. It is worth noting that the effective concentrations of GAA in vitro (0–100 μM) are higher than the biochemically determined KD values (4.84 μM by SPR and 10.02 μM by MST). This apparent discrepancy is a well-recognized phenomenon in drug discovery [52], attributable to several factors: (i) cell-free binding assays measure primary physical interaction in simplified buffer systems, whereas cellular assays integrate additional variables such as membrane permeability, intracellular protein binding, active efflux, and metabolic stability; (ii) serum proteins in culture medium bind a fraction of GAA, reducing the free concentration available for target engagement; and (iii) osteogenic differentiation is a complex, sustained process requiring prolonged signaling, not merely transient receptor occupancy. The 2-fold difference between the two KD values (SPR vs. MST) is within the acceptable range for orthogonal biophysical methods [53]. Therefore, the observed cellular efficacy is consistent with specific ERα binding and does not indicate non-specific effects. Despite these promising findings, several limitations warrant consideration. First, although the mouse model is well-established for studying OF repair, it may not fully recapitualte the complexity of human fracture healing. Translational challenges are well recognized, as several bone-targeting agents that showed robust efficacy in preclinical studies, failed to demonstrate comparable benefits in clinical trials [54]. Moreover, while the present data demonstrate that GAA enhances OF healing in both in vivo and in vitro models, these findings remain preclinical. Future studies should evaluate the therapeutic efficacy and long-term safety of GAA in clinical settings. Second, the potential impact of GAA on the early inflammatory phase of fracture healing was not directly assessed. While GAA is known to possess anti-inflammatory properties, our preliminary day-7 X-ray data showed no significant radiographic differences between the OVX fracture and GAA-treated groups. Moreover, the OVX model used in this study is not optimal for evaluating immunomodulation because estrogen itself regulates the inflammatory response [55]. Therefore, whether GAA modulates the early inflammatory microenvironment to accelerate healing remains an open question that should be investigated in non-estrogen-depleted models (e.g., normally cycling female or male animals) in future studies. Third, although serum β-CTX levels were increased in GAA-treated animals, likely reflecting enhanced overall bone turnover secondary to accelerated callus remodeling, we did not directly evaluate GAA's effect on osteoclast formation or function. The increase in β-CTX may result from indirect or coupled bone resorption rather than a direct action of GAA on osteoclasts. Conclusion In conclusion, this study provides proof-of-concept evidence that ganoderic acid A (50 mg/kg) accelerates osteoporotic fracture healing by promoting osteogenic differentiation through direct binding to estrogen receptor alpha. These findings identify GAA as a promising candidate for the development of novel therapeutic strategies aimed at improving fracture healing in osteoporotic conditions. CRediT author statement Kecheng Tang: Methodology, investigation, writing – original draft. Yiru Chen: Investigation. Yan Yu: Methodology. Zhizhen Huang: Methodology. Hang Zhang: Methodology. Yun Tian: Investigation. Min Li: Investigation. Yue Yin: Methodology. Baoxue Yang: Conceptualization, supervision, resources, writing-review & editing. Bingchuan Liu: Supervision, resources, writing-review & editing. Data availability statement Data will be made available on request. Ethics approval Female C57BL/6 mice aged 12 weeks (body weight 22–26 g) were housed under specific pathogen-free (SPF) conditions. All animal experiments complied with the guidelines of the Institutional Animal Care and Use Committee of Peking University Health Science Center (Approval No. DLASBE0725). Declaration of generative AI in scientific writing No generative artificial intelligence (AI) or AI-assisted technologies were used in the preparation of this manuscript. Funding This study was supported by grants of National Natural Scientific Foundation of China grant 82273999 and 82402476, the Proof of Concept Project of Medical Innovation Center (Taizhou) of Peking University grant CXYZ-2024-101 and Taizhou “Fengcheng Yingcai Jihua” 113 Special Project. Conflicts of interest The authors declare no conflict of interest. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.jot.2026.101173. Contributor Information Baoxue Yang, Email: baoxue@bjmu.edu.cn. Bingchuan Liu, Email: liubc@bjmu.edu.cn. Abbreviations alkaline phosphatase Alizarin Red S bone mineral density bone morphogenetic protein 2 bone volume fraction cellular thermal shift assay differentially expressed gene dual-energy X-ray absorptiometry estradiol benzoate estrogen receptor extracellular signal-regulated kinase 1/2 ganoderic acid A fulvestrant (estrogen receptor antagonist) molecular dynamics micro–computed tomography microscale thermophoresis osteoporotic fracture ovariectomized principal component analysis runt-related transcription factor 2 surface plasmon resonance trabecular number tartrate-resistant acid phosphatase Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.